List of Tables
Table 1: G8 generics industry, revenue($m), 2012-21
Table 2: G8 generics industry, revenue by country ($m), 2012-16
Table 3: G8 generics industry forecast, revenue by country ($m), 2016-21
Table 4: Canada generics market value: $ million, 2012-16
Table 5: Canada generics market volume: % of total pharma volume, 2012-16
Table 6: Canada generics market geography segmentation: $ million, 2016
Table 7: Canada generics market value forecast: $ million, 2016-21
Table 8: Canada generics market volume forecast: % of total pharma volume, 2016-21
Table 87: Canada size of population (million), 2012-16
Table 88: Canada gdp (constant 2005 prices, $ billion), 2012-16
Table 89: Canada gdp (current prices, $ billion), 2012-16
Table 90: Canada inflation, 2012-16
Table 91: Canada consumer price index (absolute), 2012-16
Table 92: Canada exchange rate, 2012-16
Table 9: France generics market value: $ million, 2012-16
Table 10: France generics market volume: % of total pharma volume, 2012-16
Table 11: France generics market geography segmentation: $ million, 2016
Table 12: France generics market value forecast: $ million, 2016-21
Table 13: France generics market volume forecast: % of total pharma volume, 2016-21
Table 14: France size of population (million), 2012-16
Table 15: France gdp (constant 2005 prices, $ billion), 2012-16
Table 16: France gdp (current prices, $ billion), 2012-16
Table 17: France inflation, 2012-16
Table 18: France consumer price index (absolute), 2012-16
Table 19: France exchange rate, 2012-16
Table 20: Germany generics market value: $ million, 2012-16
Table 21: Germany generics market volume: % of total pharma volume, 2012-16
Table 22: Germany generics market geography segmentation: $ million, 2016
Table 23: Germany generics market value forecast: $ million, 2016-21
Table 24: Germany generics market volume forecast: % of total pharma volume, 2016-21
Table 25: Germany size of population (million), 2012-16
Table 26: Germany gdp (constant 2005 prices, $ billion), 2012-16
Table 27: Germany gdp (current prices, $ billion), 2012-16
Table 28: Germany inflation, 2012-16
Table 29: Germany consumer price index (absolute), 2012-16
Table 30: Germany exchange rate, 2012-16
Table 31: Italy generics market value: $ million, 2012-16
Table 32: Italy generics market volume: % of total pharma volume, 2012-16
Table 33: Italy generics market geography segmentation: $ million, 2016
Table 34: Italy generics market value forecast: $ million, 2016-21
Table 35: Italy generics market volume forecast: % of total pharma volume, 2016-21
Table 36: Italy size of population (million), 2012-16
Table 37: Italy gdp (constant 2005 prices, $ billion), 2012-16
Table 38: Italy gdp (current prices, $ billion), 2012-16
Table 39: Italy inflation, 2012-16
Table 40: Italy consumer price index (absolute), 2012-16
Table 41: Italy exchange rate, 2012-16
Table 42: Japan generics market value: $ billion, 2012-16
Table 43: Japan generics market volume: % of total pharma volume, 2012-16
Table 44: Japan generics market geography segmentation: $ billion, 2016
Table 45: Japan generics market value forecast: $ billion, 2016-21
Table 46: Japan generics market volume forecast: % of total pharma volume, 2016-21
Table 47: Japan size of population (million), 2012-16
Table 48: Japan gdp (constant 2005 prices, $ billion), 2012-16
Table 49: Japan gdp (current prices, $ billion), 2012-16
Table 50: Japan inflation, 2012-16
Table 51: Japan consumer price index (absolute), 2012-16
Table 52: Japan exchange rate, 2012-16
Table 53: Russia generics market value: $ million, 2012-16
Table 54: Russia generics market volume: % of total pharma volume, 2012-16
Table 55: Russia generics market geography segmentation: $ million, 2016
Table 56: Russia generics market value forecast: $ million, 2016-21
Table 57: Russia generics market volume forecast: % of total pharma volume, 2016-21
Table 58: Russia size of population (million), 2012-16
Table 59: Russia gdp (constant 2005 prices, $ billion), 2012-16
Table 60: Russia gdp (current prices, $ billion), 2012-16
Table 61: Russia inflation, 2012-16
Table 62: Russia consumer price index (absolute), 2012-16
Table 63: Russia exchange rate, 2012-16
Table 64: United Kingdom generics market value: $ million, 2012-16
Table 65: United Kingdom generics market volume: % of total pharma volume, 2012-16
Table 66: United Kingdom generics market geography segmentation: $ million, 2016
Table 67: United Kingdom generics market value forecast: $ million, 2016-21
Table 68: United Kingdom generics market volume forecast: % of total pharma volume, 2016-21
Table 69: United Kingdom size of population (million), 2012-16
Table 70: United Kingdom gdp (constant 2005 prices, $ billion), 2012-16
Table 71: United Kingdom gdp (current prices, $ billion), 2012-16
Table 72: United Kingdom inflation, 2012-16
Table 73: United Kingdom consumer price index (absolute), 2012-16
Table 74: United Kingdom exchange rate, 2012-16
Table 75: United States generics market value: $ billion, 2012-16
Table 76: United States generics market volume: % of total pharma volume, 2012-16
Table 77: United States generics market geography segmentation: $ billion, 2016
Table 78: United States generics market value forecast: $ billion, 2016-21
Table 79: United States generics market volume forecast: % of total pharma volume, 2016-21
Table 80: United States size of population (million), 2012-16
Table 81: United States gdp (constant 2005 prices, $ billion), 2012-16
Table 82: United States gdp (current prices, $ billion), 2012-16
Table 83: United States inflation, 2012-16
Table 84: United States consumer price index (absolute), 2012-16
Table 85: United States exchange rate, 2012-15
Table 86: Apotex, Inc.: key facts
Table 93: Les Laboratoires Servier: key facts
Table 94: STADA Arzneimittel AG: key facts
Table 95: STADA Arzneimittel AG: key financials ($)
Table 96: STADA Arzneimittel AG: key financials (€)
Table 97: STADA Arzneimittel AG: key financial ratios
Table 98: Sanofi SA: key facts
Table 99: Sanofi SA: key financials ($)
Table 100: Sanofi SA: key financials (€)
Table 101: Sanofi SA: key financial ratios
Table 102: Sawai Pharmaceutical Co., Ltd.: key facts
Table 103: Sawai Pharmaceutical Co., Ltd.: key financials ($)
Table 104: Sawai Pharmaceutical Co., Ltd.: key financials (Â¥)
Table 105: Sawai Pharmaceutical Co., Ltd.: key financial ratios
Table 106: Daiichi Sankyo Co., Ltd.: key facts
Table 107: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 108: Daiichi Sankyo Co., Ltd.: key financials (Â¥)
Table 109: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 110: Abbott Laboratories: key facts
Table 111: Abbott Laboratories: key financials ($)
Table 112: Abbott Laboratories: key financial ratios
Table 113: Krka, d. d., Novo mesto: key facts
Table 114: Krka, d. d., Novo mesto: key financials ($)
Table 115: Krka, d. d., Novo mesto: key financials (€)
Table 116: Krka, d. d., Novo mesto: key financial ratios
Table 117: Mylan N.V.: key facts
Table 118: Mylan N.V.: key financials ($)
Table 119: Mylan N.V.: key financial ratios
Table 120: Novartis AG: key facts
Table 121: Novartis AG: key financials ($)
Table 122: Novartis AG: key financial ratios
Table 123: Teva Pharmaceutical Industries Limited: key facts
Table 124: Teva Pharmaceutical Industries Limited: key financials ($)
Table 125: Teva Pharmaceutical Industries Limited: key financial ratios